AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $794.36
- 52-wk high
- $859.34
- High
- $806.14
- 52-wk low
- $538.24
- Low
- $792.00
- Prev close
- $807.65
- Mkt cap
- $80.46B
- P/E
- 19.6x
- Volume
- 526.9K
- Fwd P/E
- 14.4x
- Beta
- 0.19
- Div yield
- 0.46%
- P/S
- 5.2x
- P/B
- 2.6x
- Profit margin
- +27.9%
- Op margin
- +33.1%
- ROE
- +14.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 56.6% above what analysts expected.
Earnings per share
$8.00 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
Reports Oct 27, 2026, in 44 days
EPS expected
$14.53 to $17.68
Revenue expected
18 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.75B | $3.88B | $3.61B | $4.29B |
| Cost of what it sold | $521.6M | $584.6M | $669.4M | $576.5M |
| Gross profit | $3.23B | $3.30B | $2.94B | $3.71B |
| What it spent | ||||
| Research and development | $1.56B | $1.63B | $1.65B | $1.63B |
| Sales and admin | $657.8M | $775.0M | $647.7M | $662.1M |
| Total operating expenses | $2.21B | $2.42B | $2.29B | $2.29B |
| What was left | ||||
| Operating profit | $1.03B | $879.9M | $642.9M | $1.42B |
| Interest on debt | $19.3M | $12.2M | $12.9M | $11.0M |
| Profit before tax | $1.76B | $1.04B | $831.2M | $1.53B |
| Tax | $303.3M | $199.1M | $104.0M | $230.9M |
| Net profit | $1.46B | $844.6M | $727.2M | $1.30B |
| EBITDA | $1.92B | $1.20B | $967.3M | $1.66B |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
Tone of tracked coverage
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
NeutralSep 12Can High Tide (NASDAQ:HITI) Weather A Tougher Market?
NeutralSep 11INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline
BearishSep 11REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
BearishSep 11MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - REGN
BearishSep 11Why Is Regeneron Pharmaceuticals (REGN) Facing A New Investor Lawsuit?
BearishSep 11SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
BearishSep 11Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
NeutralSep 10
Macro
32 macro signals shaping REGN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results